Overview
Cystic, mucinous, and serous neoplasms represent a spectrum of peritoneal surface malignancies (PSMs) characterized by their varied origins, often arising from the gastrointestinal tract, ovaries, or appendix. These neoplasms can manifest as pseudomyxoma peritonei, peritoneal mesothelioma, and disseminated peritoneal tumors, respectively. They pose significant clinical challenges due to their aggressive behavior and propensity for widespread peritoneal dissemination, leading to substantial morbidity and mortality. Given their heterogeneous nature, management strategies vary widely depending on the specific subtype and extent of disease. Understanding these conditions is crucial for clinicians to optimize patient outcomes through timely and appropriate interventions. This matters in day-to-day practice as accurate diagnosis and tailored treatment approaches can significantly impact survival and quality of life for affected patients 12.Pathophysiology
The pathophysiology of cystic, mucinous, and serous neoplasms involves complex molecular and cellular mechanisms that lead to peritoneal dissemination and tumor progression. Mucinous neoplasms, particularly those originating from the appendix (pseudomyxoma peritonei), often result from ruptured appendices or adenomas that spill mucinous material into the peritoneal cavity, promoting local seeding and tumor growth. Serous neoplasms, commonly seen in ovarian cancer, typically spread via exfoliation of malignant cells into the peritoneal fluid, leading to synchronous peritoneal metastases. At the cellular level, these processes involve aberrant signaling pathways such as PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, and Wnt/β-catenin, which drive proliferation, invasion, and resistance to apoptosis. Additionally, the peritoneal microenvironment plays a critical role, with factors like inflammatory cytokines and extracellular matrix remodeling facilitating tumor cell survival and proliferation. Tumor biology further complicates management, as genetic alterations and heterogeneity within the tumor can influence treatment responses and outcomes 23.Epidemiology
The epidemiology of cystic, mucinous, and serous neoplasms varies by subtype. Pseudomyxoma peritonei predominantly affects middle-aged adults, with a slight female predominance, often arising from a ruptured appendiceal mucocele. Peritoneal mesothelioma, linked to asbestos exposure, typically presents in older adults, with a male preponderance. Serous ovarian cancers are most prevalent in postmenopausal women, with an incidence peaking around ages 55-65. Geographically, incidence rates can differ significantly, influenced by environmental factors such as asbestos exposure for mesothelioma. Over time, there has been a trend towards earlier detection and improved survival rates due to advancements in diagnostic techniques and multidisciplinary management approaches. However, precise incidence and prevalence figures are challenging to generalize due to the heterogeneous nature of these neoplasms 12.Clinical Presentation
Patients with cystic, mucinous, and serous neoplasms often present with nonspecific symptoms that can include abdominal distension, pain, weight loss, and bowel obstruction. Pseudomyxoma peritonei may present with ascites and palpable masses in the abdomen. Peritoneal mesothelioma can manifest with pleural effusions, chest pain, and respiratory symptoms, while serous ovarian cancers frequently cause pelvic pain, bloating, and changes in bowel habits. Red-flag features include rapid progression of symptoms, significant weight loss, and signs of bowel obstruction or massive ascites, which necessitate urgent evaluation. Accurate clinical presentation is crucial for timely diagnosis and intervention, guiding the need for further diagnostic workup 14.Diagnosis
The diagnostic approach for cystic, mucinous, and serous neoplasms involves a combination of clinical assessment, imaging, and histopathological confirmation. Key steps include:Differential Diagnosis:
Management
First-Line Treatment
Cytoreductive Surgery (CRS) ± Hyperthermic Intraperitoneal Chemotherapy (HIPEC):Bullet Points:
Second-Line Treatment
Systemic Chemotherapy:Bullet Points:
Refractory or Specialist Escalation
Clinical Trials:Bullet Points:
Contraindications:
Complications
Acute Complications:Long-Term Complications:
Management Triggers:
Prognosis & Follow-Up
Prognostic Indicators:Follow-Up Intervals:
Monitoring:
Special Populations
Pregnancy:Pediatrics:
Elderly Patients:
Comorbidities:
Key Recommendations
References
1 Güler E, Oğul A, Sayur V, Benli S, Özcan C, Çolak T et al.. Awareness and attitudes toward cytoreductive surgery and hyperthermic intraperitoneal chemotherapy among surgical and medical oncologists. Scientific reports 2026. link 2 Koh E. [Innovative practices in the diagnosis and treatment of peritoneal surface malignancies: insights from the 15th congress of the Peritoneal Surface Oncology Group International (PSOGI)]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 2026. link 3 Bansal VV, Witmer HDD, Lam A, Morgan RB, Godley F, Ong CT et al.. Design and Implementation of a Learner-Centered Self-Paced Peritoneal Oncology Education Program. Annals of surgical oncology 2023. link 4 Flood MP, Waters PS, Soucisse M, Ramsay R, Michael M, McCormick JJ et al.. Pelvic exenteration, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: experience and outcomes from an exenterative and peritonectomy unit. Langenbeck's archives of surgery 2021. link 5 Sugarbaker PH. Peritonectomy procedures. Surgical oncology clinics of North America 2003. link00048-6)